After achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia through the clinic.

Original title: “ReCode CEO Suliman leaves cystic fibrosis mission in mentee’s hands”

efficacy of elexacaftor tezacaftor ivacaftor in cystic fibrosis patients with severe lung disease carrying previously ineligible cftr mutations

Original title: “Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients With Severe Lung Disease Carrying Previously Ineligible CFTR Mutations.”

i know that exercise is very good for me perception of pediatric patients with cystic fibrosis about physical exercise program

Original title: “"I know that exercise is very good for me": perception of pediatric patients with cystic fibrosis about physical exercise program.”

year in review cystic fibrosis modulator therapy efficacy access and evolution

Original title: “Year in Review: Cystic Fibrosis Modulator Therapy-Efficacy, Access, and Evolution.”

lung ultrasound in children with cystic fibrosis a descriptive clinical study

Original title: “LUNG ULTRASOUND IN CHILDREN WITH CYSTIC FIBROSIS: A DESCRIPTIVE CLINICAL STUDY.”

Cystic fibrosis (CF) is a genetic disorder that causes problems with breathing and digestion.

Original title: “About Cystic Fibrosis”

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

Original title: “Sionna cystic fibrosis drug fails key trial, removing threat to Vertex”

A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.

Original title: “Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise”

cystic fibrosis associated amyloid a amyloidosis a rare but devastating complication with poor prognosis

Original title: “Cystic fibrosis-associated amyloid a amyloidosis: a rare but devastating complication with poor prognosis.”

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.

Original title: “Vertex’s biggest overhang: a rival 50 times smaller”

The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.

Original title: “AbCellera, Vertex partner on next-gen T-cell engagers”

clinical and biochemical response to elexacaftor tezacaftor ivacaftor in a patient with the rare l927p n1303k cftr genotype

Original title: “Clinical and biochemical response to elexacaftor/tezacaftor/ivacaftor in a patient with the rare L927P/N1303K CFTR genotype.”

profiling the cftr variant selectivity and off target interactions of vx 121

Original title: “Profiling the CFTR Variant Selectivity and Off-Target Interactions of VX-121.”

economic evaluation of cftr modulator therapies in cystic fibrosis a cost benefit and cost effectiveness perspective from the remedia european commission project

Original title: “Economic evaluation of CFTR modulator therapies in cystic fibrosis: a cost-benefit and cost-effectiveness perspective from the REMEDIA European commission project.”